A crossover, add-on trial of talampanel in patients with refractory partial seizures.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 12058100.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report a double-blind, placebo-controlled, crossover study of talampanel in 49 patients with refractory partial seizures. Three doses of talampanel were investigated based on differences in patients' concomitant antiepileptic drug usage. Talampanel showed efficacy in reducing seizure frequency (p = 0.001) with a median seizure reduction of 21%. Eighty percent of patients had fewer seizures on talampanel than on placebo. Dizziness (52%) and ataxia (26%) were the only significant adverse events.
Medical subject headings
- Benzodiazepines
- Epilepsies, Partial
- Excitatory Amino Acid Antagonists